BGA
TTPH

Belmont Global Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Belmont Global Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,250
Closed -$338K – 150
2013
Q4 		$338K Buy
+1,250
New +$298K 0.27% 87

Other funds holding TTPH

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Belmont Global Advisors's TTPH Position: Q1 2014 in Review

Belmont Global Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2014, closing a stake of 1,250 shares — an estimated $338K sold.

Belmont Global Advisors first reported a position in TTPH in Q4 2013 and held it in 1 quarter. The position peaked at $338K in Q4 2013. 65 funds tracked by Wall St. Rank hold TTPH as of Q1 2014.

  • Belmont Global Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Belmont Global Advisors sold 1,250 Tetraphase Pharmaceuticals, Inc. shares in Q1 2014, an estimated $338K.
  • Belmont Global Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Belmont Global Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $338K in Q4 2013.
  • 65 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2014.

Based on Belmont Global Advisors's 13F filing for Q1 2014, filed 13 May 2014.